Evidence map›Paper›PMID 32433499›Full record

ArticleBone marrow transplantation2020

Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance.

Hilit Levy-Barazany, Liat Shachnai-Pinkas, Galina Rodionov, Alex Saar, Michal Rosenzwaig, Liron Gez, Anastasia Rodin, Nitzan Marelly, Michal Abraham, Inbal Mishalian and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Hilit Levy-Barazany *Cellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Liat Shachnai-Pinkas *Cellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Galina RodionovCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Alex SaarCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Michal RosenzwaigCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Liron GezCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Anastasia RodinCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Nitzan MarellyCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Michal AbrahamGoldyne Savad Institute of Gene Therapy, Hebrew University of Jerusalem, Jerusalem, Israel.
Inbal MishalianGoldyne Savad Institute of Gene Therapy, Hebrew University of Jerusalem, Jerusalem, Israel.
Hila WildbaumHematology Department and Bone Marrow Transplantation Unit, Rambam Health Care Campus, Haifa, Israel.
Tamar KatzHematology Department and Bone Marrow Transplantation Unit, Rambam Health Care Campus, Haifa, Israel.
Yuval BaarBMT Unit, Department of Pediatric Hematology Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Shai YarkoniCellect Biotherapeutics Ltd., Kfar-Saba, Israel. shai@cellect.co.
Ronit Bakimer-KleinerCellect Biotherapeutics Ltd., Kfar-Saba, Israel.
Amnon PeledGoldyne Savad Institute of Gene Therapy, Hebrew University of Jerusalem, Jerusalem, Israel.
Tsila Zuckerman *Hematology Department and Bone Marrow Transplantation Unit, Rambam Health Care Campus, Haifa, Israel.ORCID http://orcid.org/0000-0002-6204-977X
Jerry Stein *BMT Unit, Department of Pediatric Hematology Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
Hebrew University of Jerusalem · ILRambam Health Care Campus · ILCell Medica (Switzerland) · CHSchneider Children's Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft versus host disease (GvHD) remains a limiting factor for successful hematopoietic stem cell transplantation (HSCT). T cells and antigen-presenting cells (APCs) are major components of the hematopoietic G-CSF mobilized peripheral blood cell (MPBC) graft. Here we show that a short incubation (2 h) of MPBCs with hexameric Fas ligand (FasL) selectively induces apoptosis of specific donor T cell subsets and APCs but not of CD34

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsFas Ligand ProteinLigandsMiceMice, Inbred NODStem CellsFas Ligand ProteinLigands

Identifiers

PMID32433499
PMCPMC7329633
OpenAlexW3026693466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.